Lykos治疗研究所的3份由MDMA协助的创伤后精神紧张症治疗研究论文因不道德行为被收回。 3 MDMA-assisted PTSD therapy research papers by Lykos Therapeutics were retracted due to unethical conduct.

由于其中一个研究地点的不道德行为,精神药理学收回了三份MDMA辅助治疗研究论文。 Psychopharmacology retracted three MDMA-assisted therapy research papers due to unethical conduct at one of the study sites. 影响的研究与Lykos Therapeutics有关,该公司寻求FDA批准使用MDMA辅助治疗PTSD. The affected studies were affiliated with Lykos Therapeutics, which sought FDA approval for MDMA-assisted therapy to treat PTSD. 林业发展局因缺少数据和对研究设计的关切而拒绝申请;Lykos说,收回的论文不属于林业发展局申请的一部分。 The FDA declined the application due to missing data and concerns over study design; Lykos stated the retracted papers were not part of their FDA application. 美国食品和药物管理局已要求Lykos对其MDMA辅助疗法进行额外的临床试验。 The FDA has asked Lykos to conduct an additional clinical trial for its MDMA-assisted therapy.